Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 10:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 247 matching trials from the live ClinicalTrials.gov search.
Conditions
Colorectal Cancer (CRC)
Interventions
Irinotecan, 5-Fluorouracil (bolus), 5-Fluorouracil (infusional), Leucovorin calcium, CT-322, Bevacizumab, Bevacizumab Placebo (saline solution)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Tucson, Arizona • Fountain Valley, California • Riverside, California + 9 more
Conditions
Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Interventions
Nal-IRI, Oxaliplatin, 5-FU, Trastuzumab, Pembrolizumab, Nivolumab
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, radiation therapy
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Cleveland, Ohio
Conditions
Metastatic Cancer, Cancer, Solid Tumor
Interventions
BP31510 monotherapy, BP31510 in combination with chemotherapy
Drug
Lead sponsor
BPGbio
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Sunnyvale, California • New York, New York • Houston, Texas
Conditions
Stomach Cancer, Esophageal Cancer
Interventions
Ramucirumab, Placebo, Oxaliplatin, Leucovorin, 5-Fluorouracil
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
58
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Alhambra, California + 55 more
Conditions
B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer, Lung Cancer, Lymphoma, Melanoma, Ovarian Cancer, Glioblastoma
Interventions
Nivolumab, Epacadostat, Chemotherapy
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 16 more
Conditions
Colorectal Cancer, Metastatic Cancer
Interventions
floxuridine, fluorouracil, leucovorin calcium, adjuvant therapy, conventional surgery
Drug · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2014
U.S. locations
1
States / cities
Duarte, California
Conditions
Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma
Interventions
Oxaliplatin, Docetaxel, Leucovorin, Irinotecan, 5-Fluorouracil
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Ectropion, Skin Neoplasms
Interventions
5-Fluorouracil, Normal saline
Drug · Other
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Colorectal Cancer
Interventions
RAD001, FOLFOX, Bevacizumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
Not listed
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Salt Lake City, Utah
Conditions
Pancreatic Adenocarcinoma
Interventions
REOLYSIN®, Chemotherapy, Gemcitabine, Irinotecan, Leucovorin, 5-fluorouracil, Pembrolizumab
Biological · Drug
Lead sponsor
Oncolytics Biotech
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Colon Cancer, Rectal Cancer
Interventions
FOLFIRI, E7820
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
6
States / cities
Birmingham, Alabama • West Palm Beach, Florida • Atlanta, Georgia + 3 more
Conditions
Pancreatic Adenocarcinoma Metastatic
Interventions
NANT-008, Fluorouracil Injectable Product, Avastin Injectable Product, Leucovorin Calcium Injection, Eloxatin Injectable Product
Drug
Lead sponsor
NantPharma, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
El Segundo, California
Conditions
Malignant Neoplam, Advanced Solid Tumors
Interventions
MK-2010, Pembrolizumab, 5-Fluorouracil, Leucovorin or Levoleucovorin, Oxaliplatin, Belzutifan, Gemcitabine, Cisplatin, Carboplatin, Paclitaxel, Nab-paclitaxel, Pemetrexed, Epinephrine
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
4
States / cities
Belleville, New Jersey • East Brunswick, New Jersey • Maumee, Ohio + 1 more
Conditions
Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Lymphoma, Sarcoma, Bladder Cancer, Melanoma, IDH1 Mutated Solid Tumors, IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)
Interventions
Toca 511, Toca FC
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Denver, Colorado • Miami, Florida • Houston, Texas
Completed Early Phase 1 Interventional

Actinic Keratosis Study

NCT02019355
Conditions
Actinic Keratosis
Interventions
5-fluorouracil 5% cream, Calcipotriol 0.005% ointment, Vaseline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Cancer, Colon Cancer, Colorectal Cancer, Fever, Locally Advanced, Metastatic Colorectal Cancer, Neutropenia, Rectal Cancer
Interventions
Pegfilgrastim, Placebo, Bevacizumab, Standard Chemotherapy
Drug · Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
847 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
72
States / cities
Muscle Shoals, Alabama • Jonesboro, Arkansas • Anaheim, California + 66 more
Conditions
Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
RP2, 5-Fluorouracil, Leucovorin, Oxaliplatin, Docetaxel, Pegfilgrastim, Filgrastim, Surgical Resection of Primary Tumor
Biological · Combination Product · Drug + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30, MDADI-HN, COST-FACIT, Intensity-Modulated Radiation Therapy (Arm A), Chemoradiation (Arm B)
Diagnostic Test · Behavioral · Radiation + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Conditions
Stage II Rectal Cancer, Organ Preservation, Non-operative Treatment, Rectal Cancer (Stage III), Rectal Cancer Patients
Interventions
Complete responders and Non-complete responders, Chemoradiation + EBRT Boost, Chemoradiation + HDRBT Boost
Procedure · Radiation
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 1 Interventional Results available

Study of Proton Therapy in Adjuvant Pancreatic Cancer

NCT03885284
Conditions
Resected Pancreatic Adenocarcinoma
Interventions
mFOLFIRINOX, Proton beam radiation
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Head and Neck Cancer, Lung Cancer
Interventions
Paclitaxel, Pemetrexed, 5Fluorouracil, Carboplatin, Pembrolizumab
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
11
States / cities
Elizabeth, New Jersey • Hamilton, New Jersey • Jersey City, New Jersey + 7 more
Conditions
Resectable Pancreatic Cancer
Interventions
Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable, -Oxaliplatin 85 mg/m2 IV on Day 1, -Irinotecan 180 mg/m2 IV on Day 1, -5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours
Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck
Interventions
5-Fluorouracil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
St Louis, Missouri